Evidence map›Paper›PMID 31267021›Full record

ArticleNature medicine2019

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.

Antoni Ribas, Donald Lawrence, Victoria Atkinson, Sachin Agarwal, Wilson H Miller, Matteo S Carlino, Rosalie Fisher, Georgina V Long, F Stephen Hodi, Jennifer Tsoi and 7 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance.Frontiers in cell and developmental biology · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Antoni RibasUniversity of California, Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.ORCID http://orcid.org/0000-0003-3669-8458
Donald LawrenceMassachusetts General Hospital, Boston, MA, USA.
Victoria AtkinsonGallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, Queensland, Australia.
Sachin AgarwalIndiana University Health Goshen Center for Cancer Care, Goshen, IN, USA.
Wilson H MillerSegal Cancer Centre, Montreal, Quebec, Canada.
Matteo S CarlinoWestmead Hospital, Sydney, New South Wales, Australia.
Rosalie FisherAuckland District Health Board, Auckland, New Zealand.
Georgina V LongThe University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-8894-3545
F Stephen HodiDana-Farber Cancer Institute, Boston, MA, USA.
Jennifer TsoiUniversity of California, Los Angeles, Los Angeles, CA, USA.
Catherine S GrassoUniversity of California, Los Angeles, Los Angeles, CA, USA.
Bijoyesh MookerjeeNovartis, East Hanover, NJ, USA.
Qing ZhaoMerck & Co., Inc., Kenilworth, NJ, USA.
Razi GhoriMerck & Co., Inc., Kenilworth, NJ, USA.
Blanca Homet MorenoMerck & Co., Inc., Kenilworth, NJ, USA.
Nageatte IbrahimMerck & Co., Inc., Kenilworth, NJ, USA.
Omid HamidThe Angeles Clinic and Research Institute, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID31267021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.